Extended Ischemia Times Promote Risk of HCC Recurrence in Liver Transplant Patients

Digestive Diseases and Sciences

Volumn 60, Issue 9, 2015, Pages 2832-2839

  Kornberg, Arno ^a   Witt, Ulrike ^a   Kornberg, Jennifer ^b   Friess, Helmut ^a   Thrum, Katharina ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Institute of Pathology Helios Klinikum Berlin ^*  (Germany)

Author keywords

Cold ischemia time; Hepatocellular carcinoma; Ischemia time; Ischemia reperfusion injury; Liver transplantation; PET; Warm ischemia time

Indexed keywords

ALPHA FETOPROTEIN; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; FEMALE; HUMAN; ISCHEMIA; LIVER CELL CARCINOMA; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RECURRENCE FREE SURVIVAL; TIME SERIES ANALYSIS; TREATMENT OUTCOME; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; COLD ISCHEMIA; COMPLICATION; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; LIVER TRANSPLANTATION; METABOLISM; MIDDLE AGED; REPERFUSION INJURY; RETROSPECTIVE STUDY; RISK FACTOR; SCINTISCANNING; SURVIVAL RATE; TIME FACTOR; TUMOR RECURRENCE; WARM ISCHEMIA;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COLD ISCHEMIA; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPERFUSION INJURY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; WARM ISCHEMIA;

EID: 84939566719     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3541-z     Document Type: Article

References (35)

1. Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transplant. 2011;17:44–57.
2. Ishizaki Y, Kawasaki S. The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). J Gastroenterol. 2008;43:18–26.
3. Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria–chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant. 2009;23:49–60.
4. Cheah YL, Chow P. Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies. Liver Cancer. 2012;1:183–189.
5. Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatology 2014, Article ID 706945.
6. Kornberg A, Freesmeyer M, Bärthel E, et al. F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009;9:592–600.
7. Lee JW, Paeng JC, Kang KW, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med. 2009;50:682–687.
8. Lee SD, Kim SH, Kim YK, et al. F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2013;26:50–60.
9. Cho Y, Lee DH, Lee YB, et al. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? PLoS ONE. 2014;9:e105679.
10. Zhang J, Shi ZL, Yang X, Yin ZF. Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis. World J Gastroenterol. 2014;20:142–147.
11. Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant. 2011;11:2031–2035.
12. van der Bilt JD, Kranenburg O, Nijkamp MW, et al. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology. 2005;42:165–175.
13. van der Bilt JD, Kranenburg O, Borren A, van Hillegersberg R, Borel RIH. Ageing and hepatic steatosis exacerbate ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases. Ann Surg Oncol. 2008;15:1392–1398.
14. Tsuchiya Y, Sawada S, Yoshioka I, et al. Increased surgical stress promotes tumor metastasis. Surgery. 2003;133:547–555.
15. Teoh NC. Hepatic ischemia reperfusion injury: contemporary perspectives on pathogenic mechanisms and basis for hepatoprotection—the good, bad and deadly. J Gastroenterol Hepatol. 2011;26:180–187.
16. Roayaie K, Feng S. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transplant. 2007;13:36–43.
17. Kornberg A, Küpper B, Tannapfel A, et al. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transplant. 2012;18:53–61.
18. Parrilla P, Sanchez-Bueno F, Figueras J, et al. Analysis of the complications of the piggy-back technique in 1112 liver transplants. Transplantation. 1999;31:2388–2389.
19. Ijtsma AJ, van der Hilst CS, de Boer MT, et al. The clinical relevance of the anhepatic phase during liver transplantation. Liver Transplant. 2009;15:1050–1055.
20. Klune JR, Tsung A. Molecular biology of liver ischemia/reperfusion injury: established mechanisms and recent advancements. Surg Clin N Am. 2010;90:665–677.
21. Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischemia-reperfusion injury in liver transplantation—from bench to bedside. Nat Rev Gastroenterol Hepatol. 2013;10:79–89.
22. Lim C, Broqueres-You D, Brouland JP, et al. Hepatic ischemia-reperfusion increases circulating bone-marrow-derived progenitor cells and tumor growth in a mouse model of colorectal liver metastases. J Surg Res. 2013;184:888–897.
23. Doi K, Horiuchi T, Uchinami M, et al. Hepatic ischemia-reperfusion injury promotes liver metastasis of colon cancer. J Surg Res. 2002;105:243–247.
24. Shih KC, Man K. Small-for-size liver graft injury—impact on tumor behaviour. Transplant Rev. 2010;24:1–10.
25. Oldani G, Crowe LA, Orci LA, et al. Pre-retrieval reperfusion decreases cancer recurrence after rat ischemic liver graft transplantation. J Hepatol. 2014;61:278–285.
26. Xia F, Lau WY, Xu Y, Wu L, Qian C, Bie P. Does hepatic ischemia–reperfusion injury induced by hepatic pedicle clamping affect survival after partial hepatectomy for hepatocellular carcinoma? World J Surg. 2013;37:192–201.
27. Giuliante F, Ardito F, Pulitano C, et al. Does hepatic pedicle camping affect disease-free survival following liver resection for colorectal metastases? Ann Surg. 2010;252:1020–1026.
28. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg. 2007;94:78–86.
29. Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant. 2007;7:1601–1608.
30. Ling C, Ng KTP, Shao Y, et al. Posttransplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth. J Hepatol. 2014;60:103–109.
31. Liang W, Wu L, Ling X, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012;18:1226–1236.
32. Monbaliu D, Pirenne J, Talbot D. Liver transplantation using Donation after Cardiac Death donors. J Hepatol. 2012;56:474–485.
33. Croome KP, Wall W, Chandok N, Beck G, Marotta P, Hernandez-Alejandro R. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl. 2013;19:1214–1223.
34. Nagai S, Yoshida A, Facciuto M, et al. Ischemia time impacts recurrence of hepatocellular carcinoma following liver transplantation. Hepatology. 2014. doi:10.1002/hep.27358.
35. Xu W, Cao L, Chen L, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res. 2011;17:3783–3793.